Article
Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer.
The Gulf journal of oncology - 1 May 2016
El Amarti L, Elghissassi I, Layachi M, Mrabti H, Errihani H
Abstract excerpt
Lung cancer is the leading cause of cancer-related mortality worldwide owing to its advanced-stage at the time of diagnosis. The majority of patients will require a second-line therapy after progression during first-line treatment. While treatment for NSCLC with EGFR mutation or EML4/ALK fusion, target therapy is the favored second-line therapy if not already used in first-line therapy, NSCLC with EGFR wild-type...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.